medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 2

<< Back Next >>

Med Int Mex 2022; 38 (2)

Candida sp isolation in internal medicine service and intensive care unit of a general hospital

Aguilera-Martínez V, Castillo-Pérez AE, Linares-Segovia B, Arenas R, Fernández RF

Language: Spanish
References: 17
Page: 268-274
PDF size: 510.70 Kb.


ABSTRACT

Objective: To identify positive cases of Candida sp from cultures of clinical samples obtained from hospitalized patients in the internal medicine service and intensive care unit.
Materials and Methods: Observational, prospective, descriptive study related with cultures performed from clinical samples sent at the area of Bacteriology of the Regional Hospital Pemex, Salamanca, Mexico. All samples isolated at the internal medicine service and intensive care unit from January 2017 to December 2019 were included. Associated factor were analyzed in the clinical records and fungal species were identified by CHROMagar®.
Results: A total of 2960 cultures were reviewed, 99 cases of Candida sp were found (prevalence 3.3%). 49 female cases. Older than 70 years were the most affected cases (66.7%). The largest number of cases was registered in the internal medicine service (80.8%). Most samples were from urine (64.4%) and bronchial secretion (28.3%). The most isolated species were C. albicans (67%), C. glabrata (24%), C. krusei (6%) and C. tropicalis (3%). Diabetes mellitus was the most frequent comorbidity (51.5%). The bladder catheterization (63.6%), central cage (53.5%) and intubation (32.3%) were the most associated invasive techniques.
Conclusions: C. albicans is the most isolated species in hospitalized patients of the internal medicine and intensive care unit services, especially under invasive procedures.


REFERENCES

  1. Camacho-Cardoso JL, Martínez-Rivera MA, Manzano- Gayosso P, Méndez-Tovar LJ, et al. Detección molecular de especies de Candida en especímenes de pacientes hospitalizados. Gac Med Mex 2017;153:581-589.

  2. Menzin J, Meyers JL, Friedman M, Perfect JR, et al. Mortality, length of hospitalization and costs associated with invasive fungal infections in high-risk patients. Am J Health-system Pharm 2009; 66: 1711-1717. doi: 10.2146/ ajhp080325.

  3. Méndez-Tovar LJ, Ramos-Hernández JM, Manzano-Gayosso P, García-González A, et al. Micosis sistémicas, experiencia de 11 años en el hospital de Especialidades del Centro Médico Nacional Siglo XXI del IMSS. México. Rev Mex Micol 200 2007; 25: 15-19. https://doi.org/10.33885/ sf.2007.3.997.

  4. Méndez-Tovar LJ. Micosis invasivas en pacientes inmunodeprimidos con fiebre de origen desconocido. Rev Med Inst Mex Seguro Soc 2012; 50 (6): 609-614.

  5. Gómez J, García-Vázquez E, Espinoza C, y cols. Nosocomial candidemia at a general hospital: the change of epidemiological and clinical characteristics. A comparative study of 2 cohortes (1993-1998 versus 2002-2005). Rev Iberoam Micol 2009; 26 (3): 184-188. DOI: 10.1016/j. riam.2009.02.003.

  6. Nucci M, Annaissie E. Revisando el origen de la candidemia: ¿piel o intestino?. Clin Infect Dis 2001; 33 (12): 1959-1967. https://doi.org/10.1086/323759.

  7. Quindós G. Epidemiology of candidemia and candidiasis invasive. A changing face. Rev Iberoam Micol 2014; 31 (1): 42-48. doi: 10.1016/j.riam.2013.10.001.

  8. Nucci M, Queiroz-Tellez F, Tobón A, Restrepo A, et al. Epidemiology of opportunist fungal infections in Latin America. Clin Infect Dis 2010; 51 (1): 561-570. doi: 10.1086/655683.

  9. Hernández-Hernández F, Córdova-Martínez E, Manzano Gayosso P, López-Álvarez R, et al. Frecuencia de micosis en pacientes inmunosuprimidos de un hospital regional de la Ciudad de México. Salud Pública México 2003; 45 (6): 455-461.

  10. Vega-Sánchez DC, Bernal-López LE, Villanueva-Recillass S, Arenas GR. Infecciones urinarias por Candida spp. Estudio de 29 pacientes en un hospital general. Med Int Mex 2013; 31: 19-24.

  11. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008; 46 (7): 2222-2226. doi: 10.1128/JCM.00214-08.

  12. Leroy O, Gangneux JP, Montravers P, Mira JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational, study in France 2005-2006. Crit Care Med 2009; 37 (5): 1612-1618. doi: 10.1097/ CCM.0b013e31819efac0.

  13. Lazo V, Hernández G, Méndez R. Candidiasis sistémica en pacientes críticos, factores predictores de riesgo. Horiz Med 2018; 18 (1). dx.doi.org/10.24265/horizmed.2018. v18n1.11.

  14. Estrada BD, Dávalos MA, Flores-Padilla L, Mendoza R, et al. Comparación entre métodos convencionales, CHORMagar Candida® y el método de la PCR para la identificación de especies de Candida en aislamientos clínicos. Rev Iberoam Micol 2011; 28 (1): 36-42. DOI: 10.1016/j. riam.2010.11.003.

  15. Martínez E, Eslava GJ, Gaitán CM. Candidasis cutánea: utilidad del CHROMagar Cándida en la identificación de especies. Dermatol Rev Mex 2008; 52 (3): 212-126.

  16. García-Martos P, García-Agudo R, Marín P, Tallero E. Identificación de levaduras de interés clínico en el medio de cultivo CHROMagar Candida. Rev Iberoam Micol 1988; 15: 131-135.

  17. Tobar AE, Silva OF, Olivares CR, et al. Candidiasis invasora en el paciente crítico adulto. Rev Chil Infect 2011; 28 (1): 41-49.




2020     |     www.medigraphic.com